Marianne Romeo
Corporate Officer/Principal chez MYOVANT SCIENCES LTD.
Profil
Marianne L.
Romeo is currently the Director at Bermuda Society For Healthcare Risk Management and the Head-Global Transactions & Risk Management at Myovant Sciences Ltd.
She was previously the Director & Head-Global Transactions at Sio Gene Therapies, Inc. and held the position of Managing Director at Bowring Marsh (Bermuda) Ltd.
from 2003 to 2014.
She also worked as the Head-Global Transactions & Risk Management at Roivant Sciences Ltd.
and Roivant Sciences GmbH.
Ms. Romeo has a graduate degree from Hunter College and an undergraduate degree from Tufts University.
Postes actifs de Marianne Romeo
| Sociétés | Poste | Début |
|---|---|---|
| MYOVANT SCIENCES LTD. | Corporate Officer/Principal | - |
| Bermuda Society For Healthcare Risk Management | Director/Board Member | - |
Anciens postes connus de Marianne Romeo
| Sociétés | Poste | Fin |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 01/04/2023 |
| Bowring Marsh (Bermuda) Ltd. | Chief Executive Officer | 01/01/2014 |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
| SIO GENE THERAPIES INC. | Director/Board Member | - |
Formation de Marianne Romeo
| Hunter College | Graduate Degree |
| Tufts University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
| Bermuda Society For Healthcare Risk Management | |
| Bowring Marsh (Bermuda) Ltd. | |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
